focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
Given that the significant near term revenue is expected to cone from the Pharma services (per AN's recent presentation) I doubt the fall post FDA Approval has anything to do with reimbursement codes.
'Then there will be RNS's every so often that should slowly increase the sp over the coming years.'
Or alternatively of course it is just as likely that there will be some very significant partnership / bid approach RNS's that will cause the price to grow rapidly.
I expect the roadshow week (w/c 20/6) will be the trigger for a strong turnaround, and I have a feeling that the large fall has been, in part, engineered to let Berenberg's get in at an exceptionally good risk/reward position.
I believe that there is an existing reimbursement code that can be used for the ovarian LDT - AN has mentioned this several times in the past. The existing tests to determine if a pelvic mass might be ovarian cancer (which are reimbursed under the existing code) are, as AN frequently tells us, greatly inferior to the AGL test and so the AGL test could quickly displace them.
And while we are applying for the reimbursement code for the prostate test the Solaris group can sell the test to their patients, many of whom may well be willing to pay out of pocket for a test that can save them having to have a nasty prostate biopsy.
I think it might be 0.14% rather the 1.4%
I think some people may have taken the impression from AN's interview that it will be years before anything material happens. It will certainly be the case that it will take years to grab enough market to become a massive company ($10bln plus), but in short / medium term plenty of things will happen (contracts, partnerships etc) that start the journey to get there, and these will materially increase the value of the company.
The diminishing level of month on month production decreases over the last 4 months has been very promising. If the production update on circa 17th June indicates that the production has continued to stabilise around 9000 bpd then the well could have years of life ahead of it.
Won't be long before folks start to realise that this is a cash cow.
I wonder if these changes will negate the need for a phase 1/2 in the UK. If so that is very good news as we will be able to progress to phase III (in partnership) in H1 2023. Bermudashorts or Burble's opinion on this would be very welcome.
Interesting tweet from Angle:-
'Find #ANGLE at Precision Med Expo & Summit from 24-25th May where we will be joining Integrated Gulf Biosystems on stand C06 to demonstrate our patented #Parsortix® technology. (For Research Use Only. Not For Use in Diagnostic Procedures) Visit hxxps://precisionmedexpo.com'
https://twitter.com/Parsortix/status/1528780119678062592
I wonder if we about to see another partnership being announced ?